The Quantellect read.As of Nov 19, 2026, 11 active firms cover Tango Therapeutics Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $24.00 to $69.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $46.10 sits 111% above the current $21.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-1.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy1091%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.10
+110.6% upside
Average target across 10 active firms as of Nov 19, 2026 vs $21.89 current
Highest Target$69.00
Average Target$46.10
Lowest Target$24.00
Detailed analyst forecasts for TNGX
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate TNGX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TNGX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.50 – $-0.34 · 4 analysts · +29% YoY
Next period, 4 analysts expect Tango Therapeutics Inc to earn $-0.41 a share (range $-0.50 – $-0.34), versus $-0.32 a year earlier. Full-year consensus is $-1.46, growing to $-1.80 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $2.6M next year.
Top analysts covering Tango Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNGX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$35.00+59.9% to target
Overall win rate
53%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$46.00+110.1% to target
Overall win rate
51%
+ Follow
#3
Peter Lawson
Barclays · Rank #89
Buy
$13.00-40.6% to target
Overall win rate
45%
+ Follow
#4
Andrew Berens
Leerink Partners · Rank #162
Buy
$69.00+215.2% to target
Overall win rate
53%
+ Follow
#5
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$68.00+210.6% to target
Overall win rate
42%
+ Follow
TNGX stock forecast FAQ
What is TNGX's average 12-month price target?+
The 10 active firms with a live target average $46.10 for Tango Therapeutics Inc over the next 12 months, ranging from a $69.00 high to a $24.00 low, as of Nov 19, 2026.
Is TNGX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TNGX?+
The Street-high target is $69.00 (Leerink Partners), and the Street-low is $24.00 (Piper Sandler). The average of all 10 active-firm targets is $46.10.
How many active Wall Street firms cover TNGX?+
11 active firms have a recognized rating on Tango Therapeutics Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TNGX?+
Among analysts who currently cover TNGX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $35.00 target.
What is Tango Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.50 – $-0.34) across 4 analysts. Full-year EPS is projected at $-1.46, rising to $-1.80 the following year.
How much revenue is Tango Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $2.6M next year.
Have analysts been upgrading or downgrading TNGX lately?+
As of Nov 19, 2026, 10 of 11 active firms rate TNGX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.